Weightlifter Jara MacDermott of Kensington, Maryland, accepted a two-year period of ineligibility on August 20, 2026, after a urine sample collected at the United Masters Weightlifting Federation World Championships on December 4, 2025, returned positive for canrenone, amphetamine, and testosterone or its metabolites, according to the sanction notice published by USADA. MacDermott, 50, did not test positive for a peptide. Her case involved traditional anabolic and stimulant substances without a valid Therapeutic Use Exemption. Yet the timing of her ban places it squarely inside a two-week window during which USADA issued its most pointed public warning yet about peptide use in sport.
Eight days before MacDermott's sanction became public, USADA posted a direct advisory on its X account stating that BPC-157 is prohibited under the WADA Prohibited List and cautioning that the peptide is "making its way into wellness and anti-aging treatments," as the agency wrote on August 12, 2026. The post linked to a longer explainer on the agency's site. No athlete had been publicly sanctioned for BPC-157 at that point. The warning read as preventive, aimed at a consumer base that had grown well beyond the doping-control testing pool.
That consumer base has a name in online fitness communities: the wolverine stack peptide protocol, a pairing of BPC-157 and TB-500 marketed for tissue repair and accelerated recovery. The term borrows from the Marvel character whose fictional healing factor allows him to regenerate limbs. On episode 2440 of the Joe Rogan Experience, recorded in January 2026, Rogan walked guests Matt Damon and Ben Affleck through the protocol, describing it as a recovery option for anyone dealing with soft-tissue injuries. Rogan has separately claimed that BPC-157 resolved his own elbow tendinitis within two weeks, as reported by the Genetic Literacy Project in an August 24, 2026, commentary. Health and Human Services Secretary Robert F. Kennedy Jr. discussed his personal peptide use on the same podcast in February 2026 and signaled that regulatory changes were coming, according to reporting by The Guardian.
The language that moves through gym forums, TikTok clips, and podcast transcripts treats these compounds as recovery tools comparable to ice baths or compression sleeves. Community posts frame the wolverine stack as a biohacking shortcut rather than a pharmacological intervention. That framing collides directly with how WADA classifies BPC-157: under Category S0, Non-Approved Substances, meaning the peptide is prohibited at all times, in and out of competition, for every athlete subject to the World Anti-Doping Code. There is no Therapeutic Use Exemption pathway for a substance that lacks approved human safety and efficacy data.
An FDA Advisory Vote That Changes Nothing for Athletes
On July 23, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend adding six peptides, including BPC-157 and TB-500, to the Section 503A Bulks List. The vote would allow compounding pharmacies to legally prepare these substances if formal rulemaking follows. Wired reported that committee members evaluated BPC-157 for ulcerative colitis and that several members held financial interests in peptide clinics. Brigham Buhler, a wellness clinic owner whose client roster includes Rogan, testified in favor of expanded access, according to Washington Times coverage of the hearing.
The vote was advisory. It did not constitute FDA drug approval. Formal rulemaking, including a public comment period and final agency action, remains pending. Still, the signal traveled fast through online communities. Posts on X and TikTok within days framed the committee vote as federal validation, blurring the distinction between a compounding-permission recommendation and a safety endorsement. For athletes subject to USADA testing, none of that regulatory movement alters the WADA Prohibited List. The banned status holds regardless of what the FDA's compounding apparatus decides.
The same regulatory gap shows up at the collegiate level. Whether a substance appears on a compounding list or a pharmacy shelf does not determine eligibility under NCAA anti-doping policy, a distinction that are peptides banned by ncaa continues to generate confusion around. USADA enforces the code for Olympic and Paralympic sport. The NCAA maintains its own prohibited list. Neither body treats FDA compounding eligibility as a clearance for competition.
MacDermott's Case and the Enforcement Window
MacDermott's positive test did not involve BPC-157, TB-500, or any peptide on the WADA list. Her sample flagged canrenone, a metabolite of the diuretic spironolactone, alongside amphetamine and testosterone. These fall under separate WADA categories: diuretics and masking agents, stimulants, and anabolic androgenic steroids respectively. The substances she tested positive for are more commonly associated with older doping patterns in strength sports than with the peptide-recovery protocols circulating on wellness podcasts.
Her sanction arrived, however, inside the enforcement window USADA has drawn around peptides. The agency's August 12 social-media post named BPC-157 specifically and warned that the compound is migrating into mainstream wellness channels. Peptides Agora's coverage of the MacDermott case noted that the cultural pipeline now runs from wellness influencers and longevity clinics toward the same athlete populations USADA tests, with compounds like BPC-157 marketed alongside ghrp peptides and other growth-hormone-releasing analogues in recovery stacks. The risk USADA flagged is not limited to elite weightlifters. It extends to any athlete in a tested pool who encounters these products through a podcast recommendation or a compounding pharmacy and assumes regulatory legitimacy because a federal advisory panel discussed them.
The FDA's formal rulemaking on the six peptides has no announced timeline. Until that process concludes, compounding pharmacies operate in a gray zone for these specific compounds. WADA's prohibited list, meanwhile, updates annually, and BPC-157's S0 classification carries no sunset provision tied to FDA action. The two regulatory tracks move independently, and athletes who follow the influencer protocol without checking the code bear the full consequence of that split. MacDermott's two-year ineligibility runs from the date of her provisional suspension. USADA has not indicated whether it plans further enforcement actions in the peptide category before the next WADA list revision in January 2027.
